Literature DB >> 4396297

An analysis of graft-versus-host disease in Syrian hamsters. II. The epidermolytic syndrome: studies on its pathogenesis.

J W Streilein, R E Billingham.   

Abstract

The epidermolytic syndrome that can be obtained at will in F(1) hybrid hamsters by the cutaneous inoculation of adequate doses of parental strain lymphoid cells has been investigated to determine whether the cutaneous lesions are due to an autoimmune process arising from the severe, initial GVH reactions in the skin. It was amply demonstrated that inoculation of donor cells into the skin was of crucial importance to the development of epidermolysis. Parental strain lymphoid cells in similar doses delivered by any other route into normal F(1) hybrids failed absolutely to incite the acute syndrome. If "immune lymphocyte transfer" reactions incited by donor cells in the host's skin were surgically removed at timed intervals after inoculation, only complete excision within 24 hr prevented the appearance of epidermolysis in F(1) hybrid hosts, indicating that inoculated donor cells must remain within the confines of the skin for approximately 24 hr in order to evoke the disease, persistence for longer periods of time being unnecessary for the subsequent course of the disease. However, reconstitution experiments involving the intramuscular inoculation of suspensions containing mixtures of donor cells and host lymphoid cells, in the presence or absence of epidermal cells, unequivocally indicated that no intimate exposure of lymphoid cells to putative skin-specific antigens was essential. Similarly, the elicitation of generalized epidermolysis in F(1) hybrids irradiated with 300 r and then inoculated intravenously with donor cells casts further doubt on the pathogenic importance of the skin as a source of tissue-specific antigen. The results of subsequent experiments indicated that host leukocytes, rather than parenchymal cells of the dermis or the epidermis, were important contributors of the transplantation antigenic stimulus. Moreover, a series of experiments, using (CB x MHA)F(1) hybrid hosts that had been lethally irradiated and reconstituted with bone marrow cells from ALS-treated MHA donors, indicated that from 6 to 10 wk after reconstitution-when direct and immune lymphocyte transfer reactions showed a virtual absence of native F(1) leukocytes from the circulation-donor cells obtained from specifically sensitized MHA donors were completely ineffective in inducing epidermolysis, while equivalent lymphoid cell inocula derived from CB donors evoked the cutaneous disease irrespective of the time elapsed since reconstitution. To explain these findings it is postulated that in hamsters, the primary targets in graft-versus-host disease incited by the intracutaneous inoculation of donor cells are leukocytes originating in bone marrow or lymph node, or both.

Entities:  

Mesh:

Year:  1970        PMID: 4396297      PMCID: PMC2138749          DOI: 10.1084/jem.132.1.181

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  14 in total

1.  Pathogenesis of a local graft versus host reaction: immunogenicity of circulating host leukocytes.

Authors:  W L Elkins; R D Guttmann
Journal:  Science       Date:  1968-03-15       Impact factor: 47.728

2.  Immunization with skin isografts taken from tolerant mice.

Authors:  D Steinmuller
Journal:  Science       Date:  1967-10-06       Impact factor: 47.728

3.  Studies on heterologous anti-lymphocyte serum in mice. I. In vitro and in vivo properties.

Authors:  J G Gray; A P Monaco; M L Wood; P S Russell
Journal:  J Immunol       Date:  1966-02       Impact factor: 5.422

4.  Reactions of the graft versus host (GVH) type.

Authors:  K J Lafferty; M A Jones
Journal:  Aust J Exp Biol Med Sci       Date:  1969-02

5.  Studies on delayed cutaneous inflammatory reactions elicited by inoculation of homologous cells into hamsters' skins.

Authors:  H Ramseier; R E Billingham
Journal:  J Exp Med       Date:  1966-04-01       Impact factor: 14.307

6.  The lymph-node permeability factor: a possible mediator of experimental allergic thyroiditis in the rat.

Authors:  D A Willoughby; E Coote
Journal:  J Pathol Bacteriol       Date:  1966-10

7.  An analysis of graft-versus-host disease in Syrian hamsters. I. The epidermolytic syndrome: description and studies on its procurement.

Authors:  J W Streilein; R E Billingham
Journal:  J Exp Med       Date:  1970-07-01       Impact factor: 14.307

8.  Quaitative studies on antigenic recognition. I. Immunological and nonimmunological parameters of the response.

Authors:  H Ramseier
Journal:  J Exp Med       Date:  1969-12-01       Impact factor: 14.307

9.  Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. I. Characterization of the phenomenon.

Authors:  N H Ruddle; B H Waksman
Journal:  J Exp Med       Date:  1968-12-01       Impact factor: 14.307

View more
  5 in total

1.  Graft-versus-host reaction: a pathogenetic principle for the development of drug allergy, autoimmunity, and malignant lymphoma in non-chimeric individuals. Hypothesis.

Authors:  E Gleichmann; H Gleichmann
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1976-02-25

2.  Serum-free culture of hamster lymphoid cells and differential inhibition of lipopolysaccharide stimulation by isologous serum.

Authors:  J S Streilein; D A Hart
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

3.  Anti-leukaemia activity as a bystander effect of graft-versus-host reactions.

Authors:  P R Johnson; P Hersey
Journal:  Br J Cancer       Date:  1976-04       Impact factor: 7.640

4.  Analysis of graft-versus-host disease in Syrian hamsters. IV. The refractory state and immunologic competence.

Authors:  J W Streilein
Journal:  J Exp Med       Date:  1972-03-01       Impact factor: 14.307

5.  Cytotoxicity in graft-versus-host reaction. I. Role of donor and host spleen cells.

Authors:  J N Singh; E Sabbadini; A H Sehon
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.